Pramlintide
Also known as: Pramlintide acetate, Symlin, SymlinPen
5 notable studies · 5 references
TLDR
Pramlintide is an FDA-approved short-acting analogue of the pancreatic hormone amylin that improves postprandial glucose control and produces modest weight reduction when used alongside insulin in type 1 or type 2 diabetes, while newer long-acting amylin drugs aim to extend this established biology into more convenient and substantially more potent metabolic therapies.
Research Supports
- FDA-approved as an adjunct to mealtime insulin for postprandial glucose control in type 1 and type 2 diabetes
- Studied for effects on satiation and food intake via central amylin signaling
- Investigated for modest body-weight reduction in insulin-treated patients
- Studied as the clinical proof-of-concept for amylin-plus-incretin combination approaches
Observations Reported in Research
- In a 1-year trial, pramlintide added to insulin improved glycemic control and produced weight reduction rather than gain in type 2 diabetes (Hollander et al., 2003)
- 29-week trial of 296 people with type 1 diabetes: weight changed −1.3 kg with pramlintide vs +1.2 kg with placebo, with reduced postprandial glucose excursions (Edelman et al., 2006)
- In 212 people on basal insulin, HbA1c fell −0.70 points with pramlintide vs −0.36 with placebo at 16 weeks (Riddle et al., 2007)
- Pooled analysis of 498 insulin-treated adults found about 1.8 kg placebo-corrected weight loss at 26 weeks, with 9% losing at least 5% body weight vs 3% on placebo
- Typical HbA1c reductions across trials were approximately 0.2-0.7 percentage points
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic amylin analogue; amylin receptor agonist; pancreatic hormone analogue
Pramlintide is a synthetic analogue of amylin, a 37-amino-acid pancreatic hormone normally co-secreted with insulin after food intake. Amylin participates in post-meal glucose regulation by suppressing inappropriate glucagon secretion, slowing gastric emptying, and promoting satiation. Pramlintide was developed because native human amylin has a strong tendency to aggregate and form amyloid fibrils, making it poorly suited for pharmaceutical use. Structural modifications produced a more soluble analogue retaining important amylin-like biological activity. Unlike Cagrilintide and Eloralintide, pramlintide is FDA-approved. Its established role is as an adjunct to mealtime insulin in selected people with type 1 or type 2 diabetes. Clinical trials demonstrate improvements in postprandial glucose control, generally modest reductions in HbA1c, and small reductions in body weight. That makes pramlintide extremely useful historically: Pramlintide → first-generation, short-acting amylin analogue Cagrilintide → long-acting amylin/calcitonin receptor agonist Eloralintide → long-acting preferential amylin-receptor agonist
What Is Pramlintide?
Pramlintide is an engineered analogue of human amylin. Natural amylin is produced by pancreatic beta cells, packaged alongside insulin, and released in response to nutrient intake. In type 1 diabetes, destruction of pancreatic beta cells causes deficiency of both insulin and amylin. Amylin secretion can also become impaired in advanced type 2 diabetes. Simply administering native human amylin is problematic because the molecule readily aggregates. Pramlintide was therefore engineered with three amino-acid substitutions that greatly reduce its tendency to aggregate while preserving amylin-like pharmacological activity. Unlike the newer long-acting amylin compounds, however, pramlintide has a relatively short duration of action and is used around meals. That difference is central to understanding why newer amylin drugs were developed.
What Are Researchers Studying?
Postprandial glucose regulation
Pramlintide's strongest established physiological effect is control of glucose excursions following meals. It works alongside insulin by affecting the rate at which glucose enters the circulation, rather than simply increasing insulin secretion. Clinical studies show reductions in post-meal glucose excursions when pramlintide is added to insulin therapy. This reflects several complementary actions, including glucagon suppression and slower gastric emptying.
Type 1 diabetes
People with type 1 diabetes generally lack both endogenous insulin and endogenous amylin. This provided the original rationale for studying amylin replacement alongside insulin replacement. In a one-year randomized controlled trial, adding pramlintide to insulin improved glycemic control while producing weight reduction rather than the weight gain often associated with intensified insulin therapy. A later 29-week randomized trial involving 296 people with type 1 diabetes found particularly clear effects on postprandial glucose and body weight. Weight changed: Pramlintide: −1.3 kg Placebo: +1.2 kg while postprandial glucose excursions were significantly reduced.
Type 2 diabetes
Pramlintide has also been extensively studied as an adjunct to insulin in type 2 diabetes. A one-year randomized controlled trial demonstrated improved glycemic control and weight outcomes when pramlintide was added to insulin. A pooled analysis of insulin-treated participants approaching glycemic targets found that pramlintide reduced HbA1c while simultaneously reducing body weight. Another randomized study involving 212 people receiving basal insulin found greater improvements in HbA1c and postprandial glucose with pramlintide than placebo.
Satiation and food intake
Amylin is an important physiological meal-ending satiation signal. Its actions involve the central nervous system, particularly hindbrain pathways including the area postrema and related neural circuits. Human experiments have shown that amylin and pramlintide can reduce food intake and appetite while slowing gastric emptying. This effect helped generate interest in amylin pharmacology as an obesity-treatment strategy.
Body weight
Weight reduction with pramlintide is generally modest, especially compared with newer obesity medications. A pooled analysis of two long-term studies included 498 insulin-treated adults with type 2 diabetes who had overweight or obesity. At 26 weeks, placebo-corrected weight reduction with pramlintide was approximately 1.8 kg. Nine percent of pramlintide-treated participants lost at least 5% of their body weight versus 3% receiving placebo. This was clinically interesting because insulin treatment commonly promotes weight gain. However, these results should not be compared directly with the 15–20%+ weight reductions observed with modern obesity drugs.
Amylin + incretin combination therapy
Pramlintide helped establish the broader concept that amylin signaling can complement other metabolic pathways. Modern drug development has taken this much further. Instead of pairing short-acting pramlintide with insulin alone, researchers are now investigating long-acting amylin analogues alongside GLP-1 or GIP/GLP-1 therapies. That lineage connects pramlintide directly to compounds such as Cagrilintide and Eloralintide. Recent reviews describe pramlintide as the clinical proof-of-concept from which the newer generation of obesity-focused amylin pharmacology developed.
How Does It Work?
Pramlintide reproduces several physiological actions of endogenous amylin. Glucagon suppression Following meals, pramlintide reduces inappropriate postprandial glucagon secretion. Lower glucagon signaling reduces excessive hepatic glucose release during the post-meal period. Gastric emptying Pramlintide slows the movement of food from the stomach into the small intestine. That slows nutrient absorption and reduces the speed at which meal-derived glucose appears in circulation. Central satiation signaling Pramlintide activates amylin-sensitive neural pathways involved in meal termination and food intake. This contributes to reduced caloric intake and the modest weight reduction observed in clinical studies. Amylin receptors Amylin receptor biology is unusual. Functional amylin receptors are formed from a calcitonin receptor core associated with receptor-activity-modifying proteins (RAMPs). Different RAMP combinations create different amylin-receptor subtypes. This receptor architecture becomes especially important when comparing newer compounds such as Cagrilintide and Eloralintide.
What Does the Research Show?
Human research
Human evidence for pramlintide is extensive compared with experimental amylin peptides. Randomized trials have evaluated it in both type 1 diabetes and insulin-treated type 2 diabetes. Across studies, the overall pattern is consistent: • Reduced postprandial glucose excursions • Modest HbA1c improvement • Reduced food intake • Small average weight reductions • Potential reduction in mealtime insulin requirements A review of clinical trials reported typical HbA1c reductions of approximately 0.2–0.7 percentage points, with weight loss reaching roughly 1.6 kg in some studies. Its limitations are equally important. Pramlintide's relatively short duration requires administration around meals, and nausea is common, particularly during treatment initiation. Because it is used with insulin, hypoglycemia risk and insulin adjustment are clinically important. That makes this an especially poor compound for Aminodex to summarize merely as an “amylin weight-loss peptide.”
Animal research
Animal studies established many foundational concepts of amylin biology before they were tested clinically. Researchers demonstrated effects on: • Gastric emptying • Food intake • Satiation • Glucagon regulation • Glucose appearance • Hindbrain signaling These experiments helped identify the brain as a major site of amylin action and supported development of pramlintide as an amylin replacement strategy. Today, however, human randomized trials provide the stronger evidence for pramlintide's established clinical effects.
In-vitro research
Laboratory research was particularly important in explaining why native human amylin itself was difficult to develop as a drug. Human amylin has a propensity to aggregate into oligomers and amyloid fibrils. Pramlintide's structural modifications reduce this aggregation tendency while preserving pharmacological activity. Cellular receptor studies have also contributed to understanding the complex relationship among: • Calcitonin receptor • RAMP proteins • AMY1R • AMY2R • AMY3R That receptor biology now underlies the design of next-generation amylin therapeutics.
Notable Studies
Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-Year Randomized Controlled Trial
humanResearchers studied long-term pramlintide treatment as an adjunct to insulin in people with type 2 diabetes. Adding mealtime pramlintide improved glycemic control while producing favorable weight effects rather than additional weight gain. The trial helped establish that replacing amylin-like signaling could complement insulin therapy over extended treatment.
Limitations: The trial studied insulin-treated type 2 diabetes rather than obesity treatment in people without diabetes. The magnitude of weight reduction was modest compared with modern obesity pharmacotherapies.
View publication →Addition of Pramlintide to Insulin Therapy Lowers HbA1c in Conjunction With Weight Loss in Patients With Type 2 Diabetes Approaching Glycaemic Targets
humanResearchers analyzed insulin-treated adults with type 2 diabetes whose baseline HbA1c was 7.0–8.5%. Adding pramlintide produced further HbA1c improvement while simultaneously reducing body weight, demonstrating that improved glycemic control did not necessarily require additional weight gain.
Limitations: This was a post hoc pooled analysis rather than a separate prospectively designed trial. It applies specifically to insulin-treated type 2 diabetes.
View publication →Amylin Replacement With Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycaemic and Weight Control in Type 1 Diabetes Mellitus: A 1-Year, Randomized Controlled Trial
humanResearchers evaluated pramlintide as an amylin-replacement strategy alongside insulin in people with type 1 diabetes. Treatment improved long-term glycemic control and produced favorable weight effects, supporting the physiological concept that type 1 diabetes involves loss of both insulin and amylin signaling.
Limitations: Pramlintide remained an adjunct rather than a replacement for insulin. The trial does not establish pramlintide as a general weight-management treatment.
View publication →A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes
humanResearchers randomized 296 people with type 1 diabetes to pramlintide or placebo alongside intensive insulin therapy for 29 weeks. HbA1c declined similarly in both groups, but pramlintide produced significantly greater reductions in postprandial glucose excursions. Weight changed: Pramlintide: −1.3 kg Placebo: +1.2 kg and insulin requirements declined more substantially with pramlintide.
Limitations: The study did not demonstrate superior HbA1c reduction versus placebo under the intensive insulin-management protocol. Pramlintide requires careful integration with insulin therapy.
View publication →Pramlintide Improved Glycemic Control and Reduced Weight in Patients With Type 2 Diabetes Using Basal Insulin
humanResearchers randomized 212 adults with type 2 diabetes receiving insulin glargine to pramlintide or placebo. At 16 weeks, HbA1c declined approximately: Pramlintide: −0.70 percentage points Placebo: −0.36 percentage points Pramlintide also substantially reduced postprandial glucose excursions, and more participants achieved a composite measure of improved diabetes control without weight gain or severe hypoglycemia.
Limitations: The study lasted only 16 weeks and involved insulin-treated type 2 diabetes. It was not designed as an obesity-treatment or cardiovascular-outcomes trial.
View publication →What We Still Don't Know
Pramlintide has been available far longer than most compounds we're covering, but several questions remain relevant: • Long-term cardiovascular outcome effects • Long-term kidney outcome effects • Whether amylin signaling itself provides benefits beyond improved glycemic control and reduced food intake • Which amylin-receptor subtypes contribute most to satiation • How receptor selectivity affects nausea and other adverse effects • Whether longer-acting analogues can reproduce its metabolic benefits with substantially greater efficacy • How amylin signaling best combines with modern GLP-1/GIP therapies • Whether newer amylin analogues offer meaningful benefits independent of greater convenience • Whether amylin-based therapy can preserve lean mass differently from incretin-based obesity treatments The last several questions are exactly what Cagrilintide and Eloralintide development is beginning to address.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Pramlintide research with you.
Get the Aminodex Pramlintide Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-Year Randomized Controlled Trial. Diabetes Care. 2003;26:784–790. doi:10.2337/diacare.26.3.784.
- Ratner RE, Dickey R, Fineman M, et al. Amylin Replacement With Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycaemic and Weight Control in Type 1 Diabetes Mellitus: A 1-Year, Randomized Controlled Trial. Diabetic Medicine. 2004;21:1204–1212.
- Hollander P, Maggs DG, Ruggles JA, et al. Effect of Pramlintide on Weight in Overweight and Obese Insulin-Treated Type 2 Diabetes Patients. Obesity Research. 2004;12:661–668. doi:10.1038/oby.2004.76.
- Edelman S, et al. A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes. Diabetes Care. 2006.
- Boyle CN, Lutz TA, Le Foll C. Mediators of Amylin Action in Metabolic Control. Journal of Clinical Medicine. 2022;11:2207. doi:10.3390/jcm11082207.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.